Fique off-line com o app Player FM !
Podcasts que valem a pena ouvir
PATROCINADO
Zanubrutinib for the Treatment of Waldenstrom's Macroglobulinemia
Manage episode 321676738 series 2812899
In this episode of our podcast, we discuss the use of zanubrutinib for the treatment of Waldenstrom’s Macroglobulinemia. Our episode discusses data from the Phase 3 ASPEN trial, comparing the efficacy and safety of zanubrutinib with ibrutinib in these patients.
Our Guests
Our first guest, Dr. Constantine Tam, is a Professor of Hematology at the University of Melbourne, and Consultant Hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. He is also the lead author on the ASPEN trial, and provides a detailed look at the key data from this study.
We are then joined by Dr. Carolyn Owen, an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. Dr. Owen discusses the potential impact of the data from the ASPEN trial on Canadian clinical practice. And how zanubrutinib may fit into the Canadian treatment algorithm for Waldenstrom’s Macroglobulinemia.
This podcast episode was sponsored by Beigene Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
68 episódios
Manage episode 321676738 series 2812899
In this episode of our podcast, we discuss the use of zanubrutinib for the treatment of Waldenstrom’s Macroglobulinemia. Our episode discusses data from the Phase 3 ASPEN trial, comparing the efficacy and safety of zanubrutinib with ibrutinib in these patients.
Our Guests
Our first guest, Dr. Constantine Tam, is a Professor of Hematology at the University of Melbourne, and Consultant Hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. He is also the lead author on the ASPEN trial, and provides a detailed look at the key data from this study.
We are then joined by Dr. Carolyn Owen, an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. Dr. Owen discusses the potential impact of the data from the ASPEN trial on Canadian clinical practice. And how zanubrutinib may fit into the Canadian treatment algorithm for Waldenstrom’s Macroglobulinemia.
This podcast episode was sponsored by Beigene Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
68 episódios
Todos os episódios
×1 Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape 17:37
1 Highlights from EHA 2024 - Updates on the Treatment of CLL 42:13
1 LIVE FROM EHA 2024 - Sonrotoclax plus Zanubrutinib in R/R CLL 16:33
1 Cutting Edge Advances in the Treatment of Lung Cancer 15:13
1 Precision Medicine Series: Ep15: Biomarkers in Upper GI Cancers 41:28
1 Immunotherapy for Kidney Transplant Patients with Skin Cancer 21:32
1 Management of Cutaneous Squamous Cell Carcinoma (cSCC): A Surgeon’s Perspective 24:11
1 LIVE FROM ASH 2023: Isa-CYBORD induction chemotherapy in newly diagnosed, transplant eligible MM 16:58
1 Live from ASH 2023: Dr Brown Discusses Updated Results of the ALPINE Trial in CLL 13:48
1 First-line treatment strategies for the management of la/mUC: S2 Ep 5 - ESMO 2023: Discussion on 1L LA/mUC 32:28
1 First Line la/mUC Evolving Treatment Strategies: S2 Ep 4 - Round Table Discussion 26:41
1 First Line la/mUC Evolving Treatment Strategies: S2 Ep 3 - Case Discussion 8:07
1 First Line la/mUC Evolving Treatment Strategies: S2 Ep 2 - First-Line Treatment 14:52
1 First Line la/mUC Evolving Treatment Strategies: S2 Ep 1 - Unmet Needs 10:38
Bem vindo ao Player FM!
O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.